These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12624564)

  • 1. ALLHAT and AFFIRM.
    Liebson PR
    Prev Cardiol; 2003; 6(1):54-60. PubMed ID: 12624564
    [No Abstract]   [Full Text] [Related]  

  • 2. [ALLHAT].
    Ando K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():402-7. PubMed ID: 16981570
    [No Abstract]   [Full Text] [Related]  

  • 3. ALLHAT and ANBP2: what have we learned from recent mega-trials?
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2003; 12(4):267-71. PubMed ID: 12888711
    [No Abstract]   [Full Text] [Related]  

  • 4. ALLHAT and beyond.
    Alderman MH
    Am J Hypertens; 2003 Jun; 16(6):512-4. PubMed ID: 12799104
    [No Abstract]   [Full Text] [Related]  

  • 5. A specialist in clinical hypertension critiques ALLHAT.
    Meltzer JI
    Am J Hypertens; 2003 May; 16(5 Pt 1):416-20. PubMed ID: 12745205
    [No Abstract]   [Full Text] [Related]  

  • 6. Comments on the renal aspects of the ALLHAT study.
    Ruilope LM
    J Hypertens; 2003 Feb; 21(2):235-6. PubMed ID: 12569244
    [No Abstract]   [Full Text] [Related]  

  • 7. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
    Oparil S
    Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Simpson LM; Ghosh A; Einhorn PT; Ford CE; Probstfield JL; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2018 Aug; 110(4):343-351. PubMed ID: 30126559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALLHAT: a critical assessment.
    Sjöholm A
    Blood Press; 2004; 13(2):75-9. PubMed ID: 15182109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):485-7. PubMed ID: 12797357
    [No Abstract]   [Full Text] [Related]  

  • 12. Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Whelton PK; Williamson JD; Louis GT; Davis BR; Cutler JA
    Clin Exp Hypertens; 1996; 18(3-4):569-79. PubMed ID: 8743044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 14. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT.
    Laragh JH; Sealey JE
    Am J Hypertens; 2003 May; 16(5 Pt 1):407-15. PubMed ID: 12745204
    [No Abstract]   [Full Text] [Related]  

  • 15. ALLHAT, or the soft science of the secondary end point.
    Neely DB
    Ann Intern Med; 2004 Jul; 141(1):77. PubMed ID: 15238380
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ALLHAT trial: strengths and limitations.
    Fagard RH
    J Hypertens; 2003 Feb; 21(2):229-32. PubMed ID: 12569242
    [No Abstract]   [Full Text] [Related]  

  • 19. Guidelines for antihypertensive treatment: an update after the ALLHAT study.
    Salvetti A; Ghiadoni L
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S51-4. PubMed ID: 14684673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ALLHAT trial: a verdict or a challenge?
    Zanchetti A; Mancia G
    J Hypertens; 2003 Feb; 21(2):223. PubMed ID: 12569240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.